CLX vs IBRX · P/E 15, rev $7.10B vs rev $51.2M
The Clorox Company (CLX) versus Immunitybio Inc (IBRX) — a side-by-side from cached financials, not a winner call.
The Clorox Company (CLX) is a household & personal products company listed on US.
Immunitybio Inc (IBRX) is a biotechnology company listed on US.
Latest reported CLX revenue for 2025-06-30 was $7.10B. Net income was $824.0M. CLX currently screens at market cap $10.89B and trailing P/E 14.6.
Latest reported IBRX revenue for 2026-06-30 was $51.2M. Net income was -$230.4M. Revenue was up 15.9% from 2026-03-31 to 2026-06-30. IBRX currently screens at market cap $7.88B.
CLX currently screens at market cap $10.89B and trailing P/E 14.6. IBRX currently screens at market cap $7.88B.
Not investment advice. Open the CLX and IBRX stock pages for the full models.
Not investment advice.